Drug
Cv0701 Mrna Covid 19 Vaccine
Cv0701 Mrna Covid 19 Vaccine: highest development phase Phase 2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| CV0701 mRNA COVID-19 Vaccine (Low dose) NCT05960097 | Phase 2 | SARS-CoV-2 |
Latest
No recent events.
Follow Cv0701 Mrna Covid 19 Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.